Q3 EPS Estimate for Solid Biosciences Increased by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for shares of Solid Biosciences in a research note issued to investors on Monday, August 10th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.38) for the quarter, up from their prior estimate of ($0.41). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.63) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.41) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($1.59) EPS, FY2028 earnings at ($1.23) EPS, FY2029 earnings at $0.27 EPS and FY2030 earnings at $1.80 EPS.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Solid Biosciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a report on Friday, July 17th. Truist Financial upgraded Solid Biosciences to a “strong-buy” rating in a report on Monday, April 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $18.00 price objective (up from $17.00) on shares of Solid Biosciences in a research report on Wednesday, May 13th. Finally, Wedbush dropped their target price on Solid Biosciences from $17.00 to $16.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.11.

Solid Biosciences Price Performance

Shares of NASDAQ SLDB opened at $8.85 on Wednesday. The company has a market cap of $948.90 million, a PE ratio of -4.63 and a beta of 2.41. Solid Biosciences has a 12 month low of $3.79 and a 12 month high of $11.45. The company has a 50-day simple moving average of $8.63 and a 200-day simple moving average of $7.60.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Thursday, August 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.08.

Institutional Trading of Solid Biosciences

Several institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc raised its position in shares of Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares during the period. Creative Planning acquired a new stake in Solid Biosciences during the second quarter worth about $57,000. Russell Investments Group Ltd. increased its stake in Solid Biosciences by 142.0% during the third quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after acquiring an additional 5,991 shares during the last quarter. Polymer Capital Management US LLC purchased a new position in shares of Solid Biosciences in the 3rd quarter worth about $94,000. Finally, Jain Global LLC purchased a new position in shares of Solid Biosciences in the 4th quarter worth about $114,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Solid Biosciences’ third and fourth quarters of 2026, reducing projected losses to approximately $0.38 per share in each quarter. The firm also increased its FY2026 forecast to a loss of $1.63 per share from $1.72.
• Positive Sentiment: The analyst improved estimates across 2027 and 2028, including FY2027 EPS to a loss of $1.59 from $1.72 and FY2028 EPS to a loss of $1.23 from $1.33. These revisions suggest expectations for a faster improvement in profitability.
• Positive Sentiment: HC Wainwright also raised its FY2029 EPS estimate to $0.27 from $0.26, continuing to forecast a transition to positive earnings. The current full-year consensus remains a loss of $1.76 per share, making the revised estimates comparatively favorable.
• Neutral Sentiment: The company’s projected earnings remain negative through FY2028, so the investment case continues to depend on execution and the anticipated longer-term earnings ramp. HC Wainwright forecasts positive EPS of $0.27 in FY2029 and $1.80 in FY2030.
• Negative Sentiment: HC Wainwright trimmed its FY2030 EPS forecast to $1.80 from $1.88. Although the estimate remains strongly profitable, the reduction slightly offsets the otherwise favorable revisions.
• Neutral Sentiment: A report showing August short interest of zero shares does not provide a meaningful short-squeeze or bearish-positioning signal; the data also showed no days to cover.

About Solid Biosciences

Solid Biosciences Inc is a clinical?stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle?stabilizing protein.

Solid’s lead investigational therapy, SGT?001, is a micro?dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno?associated virus (AAV) vector.